Studies from Novo Nordisk due early next month will give the strongest indication yet of whether blockbuster GLP-1 drugs - a ...

Wellgistics Health, Inc. ("Wellgistics") (NASDAQ:WGRX), a health information technology leader at the nexus of serialization ...

LLY???s newest approvals and pipeline deals add fresh momentum to revenue growth as the company expands beyond its GLP-1 ...

Eli Lilly's tirzepatide acts on two hormonal pathways, so it's called a dual GIP/GLP-1 receptor agonist, and it entered the ...

But these eye-popping innovations have an effect only if they can make their way to the patients who need them. That reality ...

Apple became the first $1 trillion company on U.S. public markets in 2018. Six of the eight companies to follow in Apple’s ...

There are many ways to steer the ship as the top exec of a large pharma company. Here are the ones employees approve of the ...

Philadelphia is the newest destination for Lilly Gateway Labs, an incubator for early-stage biotech companies backed by pharmaceutical giant Eli Lilly & Co., the company announced Wednesday. The ...

With one in eight adults taking drugs like Ozempic and Mounjaro, emerging evidence shows that the medication has potential to ...

Novo Nordisk is quietly coming out of the storm despite the prevailing pessimism, especially among retail investors. Click ...

Orforglipron, a GLP-1 drug taken as a pill, achieved positive results in people with obesity and type 2 diabetes, although it ...

A daily pill that is cheaper and easier to take than currently available weight loss drugs helps people lose around a tenth ...